



Thrift shopping

NBPE's 2024 vintage is off to a strong start...

Update
03 July 2025

Investors understandably find it difficult to navigate choppy waters in markets, but often some of the best private equity (PE) returns come from investments made in times of market volatility and stress.

This is because PE is an active asset class, and PE managers can directly engage with and control the companies they invest in. This level of influence and ability to take action quickly is particularly valuable in times of stress, dislocation and volatility.

Private equity managers have had to negotiate myriad headwinds over the past few years, leading to lower short-term net asset value (NAV) returns. There are a few reasons for this, most notably rising interest rates and economic and geopolitical uncertainty.

Indeed, NAV returns over the past three years from listed private equity investment companies have been subdued compared with longer-term returns. The average annualised three-year return from the Morningstar Private Equity ex 3i peer group to 30/06/2025 was 1.9%, versus the average annualised five-year return of c. 8.7% and 10-year return of c. 8.9%.

Discounts have widened at the same time, leading many listed private equity fund boards to take radical action.

The reaction of listed private equity investment company managers and boards matters in times like this, in our view. When discounts remain persistently wide, capital allocation decisions must be carefully considered. Investment trusts' management and boards must carefully weigh up the pros and cons of any potential new investment against alternative uses of capital, namely buying back their own shares.

Some will argue that if a trust's shares are on a wide discount, the latter option should be exhausted before the former can be considered. On the flip side, some of the best investments are made in times of market volatility and stress.

We've been impressed by the line that **NB Private Equity Partners (NBPE)** has trodden between making new investments and buying back shares. NBPE's board announced in February 2025 that it would reserve \$120 million for share buybacks over the next three years. However, the board does believe that performance is the main determinant of discounts and has said it would be opportunistic with its use of buybacks, preferring the dividend as the main way to return capital to shareholders. NBPE has returned \$360 million via dividends over the past 10-plus years through 31/12/2024.

Analysts:

David Brenchley

david.b@keplerpartners.com




Kepler Partners is not authorised to make recommendations to Retail Clients. This report is based on factual information only.

The material contained on this site is factual and provided for general informational purposes only. It is not an invitation or inducement to buy, sell or subscribe to any product described, nor is it a statement as to the suitability or otherwise of any investments for any person. The material on this site does not constitute a financial promotion within the meaning of the FCA rules or the financial promotions order. Persons wishing to invest in any of the securities discussed in the website should take their own independent advice with regard to the suitability of such investments and the tax consequences of such investment.

With respect to making new investments, NBPE's board has previously stated that vintage diversification remains a key part of the framework used for considering buybacks. We think this is right: portfolios shouldn't only be diversified by geography, sector and sponsor; they should also have good vintage diversification.

Fig.1: Portfolio Breakdown By Vintage



Source: NBPE As at 31/03/2025

To this end, NBPE invested c. \$93 million in four new investments in 2024. We'll first note that these investments are all attractive, long-term secular growth opportunities in growing end-markets:



Benecon is a company in the health insurance sector; FDH Aero is a distributor of parts for the aerospace and defence industry; Mariner is a wealth management firm; and Zeus is a medical device company.

The investments also increased sponsor diversification, introducing four new lead sponsors to NBPE's portfolio. TA Associates, EQT, Audax Private Equity and Leonard Green & Partners are all well-known, high-quality private equity managers with a compelling value proposition for these portfolio companies.

For now, the performance of these new additions is more than justifying NBPE's decision to prioritise them over share buybacks, in our view. We understand that these investments are off to a strong start, with NBPE's 2024 vintage valued at a 1.1x gross multiple of capital, having already generated a 22% IRR on a combined basis as of 31/12/2024.

The weighted average holding period of these investments is just 0.7 years, and it's no surprise that the board is excited about the prospects for each of these businesses, which are in the early days of their value creation journey.

Despite being in their formative years, their weighted average last 12 months (LTM) revenue was 17.2% and their LTM EBITDA growth was 28.1%. For now, they are excluded from the overall portfolio growth metrics, but we look forward to seeing their progress in the coming quarters as their private equity sponsors execute their strategic and operational plans.

We'll also point out that two of the four investments are held through structured securities senior in the capital structure, which offers downside protection through minimum liquidation or return thresholds.

NBPE is mid-market focused, which is akin to mid-caps in the listed equity world, as opposed to large- and small-caps, providing a few further benefits. One of these advantages is that it gives the trust more than one exit route, meaning NBPE isn't overly reliant on a buoyant IPO market. Sales to strategic buyers and other private equity firms tend to be more popular realisation routes.

It should also be noted that NBPE is in a strong position for when realisations do start to pick up, thanks to its high-quality, mature portfolio of 5.4 years. In fact, year-to-date, NBPE has already received \$53 million with a further \$22 million of proceeds expected in the coming months.

As a reminder, NBPE partners with some of the world's leading private equity managers to invest directly into private companies as a minority investor, instead of investing into private equity funds. The early success of NBPE's 2024 vintage shows the benefits of its co-investment model, as well as its healthy balance sheet.

Unlike many of its fund of fund peers, who might be forced to do periodic, follow-on investments, even when it may not be in their best interest, NBPE effectively has no future investment commitments, meaning it is not forced to raise cash to make new investments at inopportune times.

NBPE has full control of the timing of new and follow-on investments allowing the team to start and stop investing whenever they deem it appropriate. The fact that NB decided to put cash to work last year shows confidence in the new additions to the portfolio, which sets NBPE up for the future.

In our view, share buybacks, while an important capital allocation tool, are not the silver bullet many believe them to be. They must be weighed up against potential new investments and, where the returns from the latter look more accretive to NAV than the former, new investments can be prioritised.

There are plenty of other levers to be pulled when considering narrowing the discount, including focusing on investor relations. Perhaps the changes to KID disclosures would help, too. Ultimately, though, we think it is continued strong relative NAV performance that will help to sustainably narrow the discount.

If NBPE's 2024 vintage can help to bolster performance, alongside improving sentiment as the IPO window reopens and the interest rate cutting cycle continues, we think NBPE's shares stand out as compelling value for adventurous, long-term investors on a c. 29% discount to NAV.

[View the latest research note here](#)

[Click here to add NBPE to your watchlist](#)

[Click here to read related research](#)



Disclaimer

This report has been issued by Kepler Partners LLP. **The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.**

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

